Study of VG712 for advanced mycosis fungoides
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called VG712 for people with a type of skin lymphoma called mycosis fungoides that has not responded to at least two previous treatments. The drug may help control the cancer, and the study will check if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have mycosis fungoides that has not improved after at least two prior treatments (like chemotherapy or other systemic therapies).
- You are able to do daily activities with some help (performance status 2 or less).
- Your organs (heart, kidneys, liver) are working well enough, and your oxygen level is normal without needing extra oxygen.
- You are willing to use birth control during the study and for 3 months after the last dose.
- You have recovered from side effects of previous treatments, except hair loss.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
This study tests a cream that targets inflammation in the skin for people with early-stage mycosis fungoides, a type of lymphoma. It may help relieve symptoms and slow the disease without stronger treatments.
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
This trial tests a new investigational drug (DT-7012) for people with a type of skin lymphoma that hasn't responded to standard treatments. The drug is given as an infusion and aims to boost your immune system to fight the cancer.
This Phase 2 study tests mogamulizumab together with low-dose total skin electron beam radiation to treat mycosis fungoides or Sézary syndrome, two types of skin lymphoma. It may help shrink skin disease and control symptoms by combining an immune-targeting medicine with skin-focused radiation.
This study looks for “predictive” and “prognostic” biomarkers—measurable signs in blood or tissue—to help predict how mycosis fungoides or Sézary syndrome will behave and how patients may respond to care. It may help doctors better understand outcomes for people with these skin lymphomas.
Hear when a new Mycosis Fungoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.